EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study

Mattia Cristallo iD, Ippolita Zaza, Michelina Francesca Daddato iD, Loredana Muolo, Francesco Pugliese, Alice D'Amico, Marco Casciaro iD, Sebastiano Gangemi iD, Eustachio Nettis

International Journal of Dermatology · 2026-04 · 65 (4) · 816-818

DOI: 10.1111/ijd.70049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, online erschienen am 01.09.2025. Verfasst von Mattia Cristallo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision and Regenerative Medicine and Ionian Area, Regional Reference Center for Allergic and Immunological Diseases, University of B…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eustachio Nettis has a conflict of interest with Sanofi, Abbvie, Leo Pharma, Almirall, Gsk, and Astra-Zeneca. The remaining authors have no conflicts of interest that are directly relevant to the content of this article. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Schlagwörter

Stichwörter der Autor:innen

alexithymianon‐segmental vitiligoreal‐life studyruxolitinib

Autor:innen und Institutionen

  • Department of Precision and Regenerative Medicine and Ionian Area, Regional Reference Center for Allergic and Immunological Diseases, University of Bari Aldo Moro, Bari, Italy.
  • Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

ORCID-Profile: Mattia Cristallo, Michelina Francesca Daddato, Marco Casciaro, Sebastiano Gangemi

Zitieren

APA

Cristallo, M., Zaza, I., Daddato, M. F., Muolo, L., Pugliese, F., D'Amico, A., Casciaro, M., Gangemi, S., & Nettis, E. (2026). Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study. International Journal of Dermatology, 65(4), 816-818. https://doi.org/10.1111/ijd.70049

Vancouver

Cristallo M, Zaza I, Daddato MF, Muolo L, Pugliese F, D'Amico A, et al. Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study. International Journal of Dermatology. 2026;65(4):816-818. doi:10.1111/ijd.70049

BibTeX
@article{Cristallo2026,
  author = {Cristallo, Mattia and Zaza, Ippolita and Daddato, Michelina Francesca and Muolo, Loredana and Pugliese, Francesco and D'Amico, Alice and Casciaro, Marco and Gangemi, Sebastiano and Nettis, Eustachio},
  title = {Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study},
  journal = {International Journal of Dermatology},
  year = {2026},
  volume = {65},
  number = {4},
  pages = {816--818},
  doi = {10.1111/ijd.70049}
}
Kostenlos starten →